<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>An assay of high sensitivity and specificity for detection of residual malignant cells in remission bone marrow from patients with <z:hpo ids='HP_0006721'>acute lymphoblastic leukemia</z:hpo> (ALL) and non-Hodgkin's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (NHL) has been developed </plain></SENT>
<SENT sid="1" pm="."><plain>The assay combines an immunoselection step with immunoglobulin gene rearrangement analysis by high specific-activity DNA probes </plain></SENT>
<SENT sid="2" pm="."><plain>In experimental conditions, less than one contaminating <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cell out of 1000 bone marrow cells was detected </plain></SENT>
<SENT sid="3" pm="."><plain>A bone marrow contamination was detected in morphologically negative bone marrow specimens from two intermediate-grade non-Hodgkin's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> patients </plain></SENT>
<SENT sid="4" pm="."><plain>This method can be of value in determining a true remission status in high-risk ALL and NHL patients </plain></SENT>
</text></document>